University of Rhode Island

DigitalCommons@URI
Pharmacy Practice Faculty Publications

Pharmacy Practice

6-2013

Antipsychotic Prescribing Pathways, Polypharmacy, and
Clozapine Use in Treatment of Schizophrenia
Jessica L. Gören
University of Rhode Island, jgoren@challiance.org

Mark Meterko
Sandra Williams
Gary J. Young
Errol Baker

See
next
page
additional
authors
Follow
this
andfor
additional
works
at: https://digitalcommons.uri.edu/php_facpubs

The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access
Policy Articles, as set forth in our Terms of Use.
Citation/Publisher Attribution
Gören, J. L., Meterko, M., Williams, S., Young, G. J., Baker, E., Chou, C.H., Kilbourne, A. M., & Bauer, M. S.
(2013). Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in Treatment of
Schizophrenia. Psychiatric Services, 64(6), 527-533. doi: 10.1176/appi.ps.002022012
Available at: http://dx.doi.org/10.1176/appi.ps.002022012

This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has
been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of
DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors
Jessica L. Gören, Mark Meterko, Sandra Williams, Gary J. Young, Errol Baker, Chia-Hung Chou, Amy M.
Kilbourne, and Mark S. Bauer

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/66

Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in
Treatment of Schizophrenia
Jessica L. Gӧren, PharmD
Mark Meterko, PhD
Sandra Williams, MS
Gary J. Young, JD, PhD
Errol Baker, PhD
Chia-Hung Chou, PhD
Amy M. Kilbourne, PhD, MPH
Mark S. Bauer, MD

Dr. Gören is affiliated with the Department of Pharmacy Practice, University of Rhode Island,
Kingston (e-mail: jgoren@challiance.org address 1035 Cambridge St, Suite 23, Cambridge, MA
02141).
Dr. Gören, Dr. Meterko, Ms. Williams, Dr. Young, Dr. Baker, and Dr. Bauer are with the
Veterans Affairs (VA) Center for Organization, Leadership and Management Research, VA
Boston Healthcare System, Boston.
Dr. Young is with the Center for Health Policy and Healthcare Research and Dr. Chou is with
the School of Pharmacy, both at Northeastern University, Boston.
Dr. Kilbourne is with the Health Services Research and Development Service, Center for
Clinical Management Research, VA Ann Arbor, Ann Arbor, Michigan.

1

Objective: To ensure optimal care for patients with schizophrenia, antipsychotic medications
must be appropriately prescribed and used. Therefore, the primary objectives of this study were
to identify and describe pathways for antipsychotic prescribing, assess the consistency of
observed pathways with treatment guidelines, and describe variability across facilities.
Methods: Data from Veterans Affairs administrative data sets from fiscal year (FY) 2003 to FY
2007 were gathered for analysis in this retrospective cohort study of antipsychotic prescribing
pathways among 13 facilities across two regional networks. Patients with a new episode of care
for schizophrenia or schizoaffective disorder in FY 2005 were identified, and antipsychotic
prescribing history was obtained for two years before and after the index diagnosis.
Demographic characteristics and distribution of comorbidities were assessed. Median medical
center rates of polypharmacy were calculated and compared with Fisher’s exact test.
Results: Of 1,923 patients with a new episode of schizophrenia care, 1,003 (52%) had complete
data on prescribing pathways. A majority (74%) of patients were prescribed antipsychotic
monotherapy, and 19% received antipsychotic polypharmacy. Of patients receiving antipsychotic
polypharmacy, 65% began polypharmacy within 90 days of starting any antipsychotic treatment.
There was a fourfold difference in polypharmacy across facilities. Antipsychotic polypharmacy
was not associated with geographic location or medical center patient volume. Clozapine
utilization was low (0%–2%).
Conclusions: Retrospective examination of longitudinal prescribing patterns identified multiple
antipsychotic prescribing pathways. Although most patients received guideline-concordant care,
antipsychotic polypharmacy was commonly used as initial treatment, and there was substantial
variability among facilities. Study findings suggest the utility of secondary data to assess
treatment adaptation or switching for practical clinical trials.
Although antipsychotics are effective for the treatment of schizophrenia, many patients do
not respond to the first antipsychotic prescribed (1–3). Patients without a response on a second
antipsychotic trial are typically considered treatment resistant (4–10). Because clozapine is the
only antipsychotic proven effective for treatment-resistant schizophrenia, it is widely recognized
as the preferred treatment option for patients who have not responded to two antipsychotic
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monotherapy trials (4–10). This approach is reflected in evidence-based treatment guidelines,
which recommend that such patients be offered clozapine (6–10).
With these evidence-based treatment guidelines, one can conceptualize guideline-concordant
treatment as an antipsychotic (AP) prescribing pathway, whereby AP1AP2clozapine.
However, studies indicate that adherence to this guideline is low (11–25). Increasingly, longterm use of two or more regularly scheduled antipsychotics (polypharmacy) is prescribed, often
before clozapine (11,15,17–19,23–25). This practice is inconsistent with evidence-based
guidelines, which do not endorse long-term antipsychotic polypharmacy and recommend it only
as a last-line treatment when clozapine has failed (6–10).
Rates of clozapine and antipsychotic polypharmacy use vary by treatment setting (11–25).
However, most studies to date on antipsychotic prescribing have been cross-sectional even
though longitudinal assessment is required to characterize appropriate use of polypharmacy.
Cross-sectional studies cannot make the important distinction between antipsychotic
polypharmacy use for treatment-resistant individuals (such as after a failed clozapine trial) and
for other, less discriminating use. Also, findings from cross-sectional studies do not provide
necessary information to assess which patients may be eligible for clozapine (11,16,20). This is
of particular importance because the longitudinal studies that have been conducted indicate that
clozapine is started after the failure of an average of six antipsychotic trials, including a period of
antipsychotic polypharmacy, suggesting that the most effective treatment for treatment-resistant
patients is delayed or not used (17–19,24,25).
Longitudinal studies of large administrative data sets are becoming increasingly important.
The development of more cost-efficient adaptive and practical clinical trials could be informed
by data from existing sources. Also, studies examining the impact of policy or implementation
strategies on prescribing pathways can be done in a naturalistic setting, guiding development of
interventions that may be successful in real-world applications. Ultimately these studies may
improve use of guideline-based treatment and outcomes in mental health.
Therefore the goals of this descriptive retrospective cohort study were to use administrative
data to develop a systematic method for describing longitudinal antipsychotic prescribing
pathways and to describe the observed sequence of antipsychotic trials as related to evidencebased guideline recommendations.
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Methods
Setting and data sources
The Veterans Health Administration (VHA) is a national health care system treating >87,000
veterans with schizophrenia or schizoaffective disorder annually. Because the VHA has used
electronic records for clinical care for many years, readily available administrative data sets can
be used to identify and describe longitudinal antipsychotic prescribing pathways. Administrative
data have been used extensively in other antipsychotic studies (11,20,26–28).
We focused on 13 medical centers across two Veterans Affairs (VA) Integrated Service
Networks (VISNs). We chose two VISNs in different regions of the United States that serve a
large number of veterans with schizophrenia or schizoaffective disorder. Data to identify our
target sample and characterize individuals’ medication history were obtained from the VA
National Patient Care Database (NPCD), which contains information on inpatient and outpatient
visits, ICD-9-CM diagnoses and procedure (CPT-4) codes, dispensed medication, and patient
demographic characteristics. Data on average patient volume were derived from the fiscal year
(FY) 2004 VA National Psychosis Registry (NPR) report, which includes data from multiple
sources for all veterans treated for psychoses within the VHA.
Study sample
We identified all patients from two VISNs who received a prescription for an antipsychotic and
were actively engaged in ongoing treatment, with a new episode of care for spectrum disorders in
FY 2005. We focused on new episodes of care because treatment recommendations begin with
the first treatment chosen for an episode of illness.
A new episode of care was defined as an ICD-9-CM schizophrenia-related diagnosis (codes
205.0–295.9) in at least one inpatient or two outpatient encounters in FY 2005, no schizophreniarelated diagnosis in the previous two years, initiation of an index antipsychotic prescription, and
no antipsychotic prescription for daily use >90 days in the year before the diagnosis. Patients
with multiple psychiatric disorders coded on the diagnosis date were included if the number of
schizophrenia-related diagnoses exceeded or equaled the number of other psychiatric disorders
(20). Patients had to be actively engaged in VHA treatment, as evidenced by at least one VHA

4

outpatient visit for any medical or psychiatric disorder in both FY 2006 and FY 2007. The
Boston VHA institutional review board approved this study.
Antipsychotic use
Antipsychotic use was defined as any dose of an antipsychotic (American Hospital Formulary
Service class 28:16.08) for daily use dispensed from an outpatient VHA pharmacy for 90 days
in FY 2005. The 90-day criterion was chosen on the basis of previous studies in which
discontinuation of treatment due to adverse events versus inefficacy occurred earlier in treatment
(25).
The index antipsychotic prescription was defined as the first antipsychotic prescribed for
daily use in FY 2005. To minimize the likelihood of falsely categorizing as polypharmacy
transitions from one antipsychotic to another, we defined polypharmacy as concomitant
prescription of two antipsychotics for daily use for >90 days (11). Intermittent exposures of 90
days were considered noninformative.
Informative sample
Each patient’s prescribing pathway was characterized according to the antipsychotic trials
received during the two years after the index antipsychotic trial. As summarized in Figure 1,
receipt of a single antipsychotic other than clozapine for daily use (pathway 1) or two sequential
prescriptions for regularly scheduled nonclozapine antipsychotics (pathway 2) with no gaps >90
days for the duration of the study was categorized as monotherapy. Receipt of two prescriptions
concomitantly for >90 days was categorized as polypharmacy. Antipsychotic polypharmacy
could occur at various points in the treatment sequence (pathways 3–6). Patients who received
clozapine for daily use as the second or third monotherapy trial were categorized as receiving
early clozapine (pathway 8) or clozapine (pathway 7), respectively. Patients who received three
or more sequential nonclozapine antipsychotics were categorized as delayed use of clozapine
(pathway 9). Because prescription history data were available to definitively characterize
pathways 1–9, we refer to them collectively as informative cases.
Noninformative cases
Some observed pathways were noninformative because incomplete information made a
categorization ambiguous or uncertain. For example, some cases received a single trial (pathway
5

11) or sequential trials of antipsychotics (pathway 10) but no further antipsychotic prescriptions
during the observation period. Thus it was not possible to characterize these pathways.
Characterization of antipsychotic pathways
Pathways 1, 2, and 7 represent guideline-endorsed antipsychotic prescribing pathways and thus
were characterized as guideline concordant. In cases of extreme suicidality or aggression,
guidelines endorse using clozapine as the second antipsychotic, so pathway 8 was categorized as
guideline concordant (6). Pathways 3–6 all involved polypharmacy before clozapine was
prescribed, and these pathways were categorized as guideline nonconcordant. Antipsychotic
polypharmacy including clozapine was considered guideline nonconcordant because clozapine
monotherapy was not used before polypharmacy was initiated. Pathway 9 involved use of a
nonclozapine antipsychotic after two failed antipsychotic trials and was categorized as
nonconcordant with guidelines. Pathways with clozapine as the first antipsychotic were excluded
from the study because these likely reflect treatment-resistant patients for whom standard
guideline-concordant care may not be appropriate.
Analytic sample
Previous studies have demonstrated that antipsychotic monotherapy and polypharmacy are the
most common forms of antipsychotic treatment (12–14). These antipsychotic prescribing
pathways also have the clearest relationship to guideline recommendations. Hence these groups
formed the analytic sample and were used to address the second major aim of the study,
comparison of prescribing practices with treatment guidelines. Because patients requiring
clozapine treatment represent either more severely ill or treatment-resistant populations, they
were excluded from the analytic sample.
Measures and analyses
Our measures and analyses proceeded at both the patient and facility center levels. At the patient
level, our primary dependent variable was pathway assignment. Using the ICD-9-CM diagnosis
codes associated with each medical encounter during the study, we created presence and absence
variables for the antipsychotic-related comorbidities diabetes and hyperlipidemia. From the
NPCD we obtained five demographic characteristics: age at time of the index visit, marital status
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(four categories), gender, self-reported race (U.S. Census categories), and self-reported ethnicity
(whether, yes-no, patients considered themselves Hispanic, Latino, or Spanish).
We used basic frequencies, central tendency, and variance statistics to describe the number of
cases in each of the antipsychotic pathway groups as well as the demographic and comorbidity
profiles of all informative cases and the analytic sample. Within the analytic sample, we
compared the demographic characteristics and distribution of comorbidities between
monotherapy and polypharmacy groups by computing chi square statistics on the crosstabulation of antipsychotic pathway (monotherapy and polypharmacy) by those categorical
variables. For age, we computed independent-groups t tests between monotherapy and
polypharmacy.
At the medical center level, we computed a polypharmacy rate as the percentage of cases in
the analytic sample at that medical center that fell into the monotherapy and polypharmacy
pathways. The denominator for this rate was the total number of cases in our analytic sample: the
combined monotherapy and polypharmacy groups. As a measure of the total volume of patients
with severe mental illness (psychotic and bipolar disorders), we obtained counts of such cases for
each medical center from the NPR. Finally, because facilities were located in two geographically
diverse VISNs, a dichotomous categorical location code was created to represent region
(designated A or B). For analyses at the medical center level, we used basic descriptive statistics
to describe the distribution of polypharmacy rates.
To examine the association between polypharmacy rate and geographic region, we computed
the median polypharmacy rate at the medical center level, classified facilities as above or below
that rate, and computed the Fisher exact probability test on the cross-tabulation of polypharmacy
rate (below or above median) by region. Finally, to examine the association between
polypharmacy rate and volume of patients with severe mental illness, we computed the facility
median for volume of these patients, classified facilities as being above or below that volume,
and then computed the Fisher exact probability test on the cross-tabulation of polypharmacy rate
(below or above median) and volume of patients with severe mental illness (below or above
median).
Results
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We identified 1,923 new treatment episodes of schizophrenia and schizoaffective disorders in FY
2005 and their distribution across nonredundant pathway groups (Table 1). Of the total, 310
(16%) veterans did not utilize VHA outpatient services in FY 2006 and FY 2007. Another 338
(18%) utilized VHA services but did not receive antipsychotic medications from an outpatient
VHA pharmacy in FY 2005, and 272 (14%) did not receive a sufficient number of antipsychotic
prescriptions to allow reasonable judgment about appropriate pathway assignment. These 920
noninformative cases (48%) were not included in further analyses. There was no difference in
median age between the informative and noninformative groups.
The remaining 1,003 informative cases involved patients who entered a new treatment
episode for schizophrenia or schizoaffective disorder, were treated with an antipsychotic in FY
2005–FY 2007 and had one or more outpatient clinic visits in FY 2006 and FY 2007. Within the
informative sample, 763 patients (76%) received care consistent with treatment guidelines (Table
1). The most common guideline-concordant prescribing pathway was monotherapy (N=745,
74%), followed by early use of clozapine (N=17, 2%). One patient received clozapine after two
antipsychotic trials. The remaining 24% (N=240) of informative cases followed prescribing
pathways that were nonconcordant with guidelines, with nonclozapine polypharmacy being the
most common path (N=188, 19%). Notably, of patients receiving antipsychotic polypharmacy,
65% (N=127) received polypharmacy as their first antipsychotic treatment and 4% (N=45)
received polypharmacy in place of clozapine.
A total of 933 informative cases (93%) qualified for the analytic sample, which for reasons
discussed above consisted of the (nonclozapine) antipsychotic monotherapy (N=745) and
(nonclozapine) polypharmacy (N=188) pathway groups. Self-reported race and ethnicity were
missing in 49% and 51% of cases, respectively. The descriptive statistics for these variables and
the chi square analyses were based, respectively, on persons whose race (N=474) or ethnicity
(N=454) was known. The analytic sample was predominantly single (45%), Caucasian (54%),
and male (93%) (Table 2), with a mean±SD age of 50.7±12.2. The incidence of diabetes and
hyperlipidemia was 16% and 17%, respectively.
There were no statistically significant associations between pathway group and demographic
characteristics or comorbidities, with three exceptions. Six percent of the nonclozapine
monotherapy sample was female compared with 13% of the nonclozapine polypharmacy group
8

(2=9.39, df=1, p<.01), and 52% of the monotherapy group was Caucasian compared with 65%
of the polypharmacy group (2=8.54, df=3, p<.05). A significant association was observed with a
higher proportion of hyperlipidemia in the polypharmacy group (22%) compared with the
monotherapy group (15%; 2=4.38, df=1, p<.05).
We observed a more than fourfold difference in antipsychotic polypharmacy rates between
the medical centers (Figure 2). The median medical center polypharmacy rate was 21%, and the
likelihood of being above that rate was no greater in region A compared with region B (p=.59, by
Fisher exact test). The median annual medical center volume of cases of severe mental illness
was 1,616, and the likelihood of being above or below the median polypharmacy rate for a
facility was no greater at lower-volume facilities compared with higher-volume facilities (p=.10,
by Fisher exact test).
Discussion
Using retrospective data of longitudinal antipsychotic prescribing, we classified 1,003 of 1,923
patients (52%) with new treatment episodes of schizophrenia into one of 11 antipsychotic
prescribing pathways. Of these informative cases, 74% were treated along antipsychotic
monotherapy pathways, consistent with treatment guidelines. This is consistent with estimates
that 70%–80% of patients with schizophrenia are responsive to treatment (1,2).
We found that 24% of patients received care nonconcordant with guidelines, primarily
involving antipsychotic polypharmacy. A total of 13% of informative cases received
polypharmacy before receiving a monotherapy antipsychotic trial. This rate is 3.5 times higher
than previously reported in the California Medicaid population (29). This discrepancy is most
likely related to methodological differences. Whereas the Medicaid study reported antipsychotic
polypharmacy as the initial treatment for patients who received prescriptions for two
antipsychotics at the first fill, our study defined polypharmacy as initial treatment when patients
did not receive an adequate monotherapy trial of antipsychotic before receiving antipsychotic
polypharmacy. Thus, for our population, initial treatment with antipsychotic polypharmacy
included patients who received polypharmacy within the first 90 days of treatment. The fact that
65% of patients treated with polypharmacy started antipsychotic polypharmacy within the first
90 days of treatment indicates that a majority of patients on polypharmacy were not treated with
a single evidence-based treatment. In summary, both studies suggest that antipsychotic
9

polypharmacy is often being used as the initial treatment, contravening all evidence-based
guidelines.
Similar to other studies, our study showed a significant difference among medical centers in
utilization of antipsychotic polypharmacy, and this variability was not associated with
geographic region or volume of patients with severe mental illness. Previous studies indicated
that clinicians reserve antipsychotic polypharmacy for patients with more severe illness.
However, it seems unlikely there would be a fourfold difference in the number of severely ill
patients between facilities and that 65% of patients receiving polypharmacy were so sick that
they required antipsychotic polypharmacy as first-line treatment (30). Thus future research
should investigate whether organizational characteristics account for some variability in
antipsychotic prescribing. For example, differences in availability of resources, staffing, quality
improvement capability, program implementation, care coordination, and communication may
affect provision of care (26,31–33). The organization and provision of care have been shown to
vary among VHA mental health programs, which may contribute to the observed variation
(31,33).
Medical centers with lower volume of patients with severe mental illness trended toward
higher rates of polypharmacy. Whereas five of six low-volume medical centers had higher rates
of polypharmacy, five of seven high-volume medical centers had lower rates of polypharmacy,
suggesting that more experience with severe mental illness may be related to increased
adherence with treatment guidelines.
Clozapine underutilization is an issue in the treatment of schizophrenia and schizoaffective
disorders, possibly because of increased prescribing burden, including prescriber and patient
registration requirements; significant side-effect burden; and frequent laboratory testing to
monitor for side effects. In this study, only about 2% (N=18) of patients in the informative
sample received clozapine consistent with evidence based guidelines, whereas 45 patients who
fared poorly on two antipsychotic trials did not receive clozapine. Some of these cases may
reflect antipsychotic intolerance rather than clozapine nonresponse. However, given that up to
20% of patients with schizophrenia are treatment resistant whereas under 2% of patients received
clozapine and almost 19% received antipsychotic polypharmacy, it seems unlikely that use of
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clozapine is optimized. It is concerning that patients may be receiving polypharmacy in place of
clozapine or that initiation of clozapine is delayed.
Consistent with other studies, receipt of antipsychotic polypharmacy was more common with
women and Caucasian patients (29,34). Our finding that patients receiving antipsychotic
polypharmacy were more likely to have hyperlipidemia is contrary to at least one previous study
(35). However, antipsychotic polypharmacy may be a marker for factors such as body mass
index and concomitant medications that were not controlled for in this study.
It is interesting to note that 338 patients diagnosed as having schizophrenia or schizoaffective
disorder received care within the VHA but did not receive antipsychotics. Some of these patients
may fill their prescriptions outside the VHA. It is also possible that these patients had less severe
illness or chose not to fill antipsychotic prescriptions and therefore represent a population in need
of outreach.
Conclusions
To our knowledge, this study is unique in its description and categorization of antipsychotic
prescribing pathways. Our method allowed for identification of justified deviations from
treatment guidelines and of patients possibly eligible for a clozapine trial. Nonetheless, there are
some limitations that should be noted. Data derived from prescription files do not account for
nonadherent patients, and the filling of a prescription does not necessarily mean that the
medications were taken how and when they should have been. Given that this study did not focus
on treatment outcomes, however, this limitation is not a critical concern. Also, such data cannot
account for patient and clinician preferences. Medication changes may have been secondary to
drug intolerance rather than inefficacy, and thus all 45 patients with two unsuccessful sequential
trials of monotherapy may not have been appropriate for a clozapine trial. However, the use of
the 90-day minimum to identify an antipsychotic trial in this study makes this somewhat less
likely.
Consistent with prior cross-sectional analyses, we observed that 19% of patients with
schizophrenia treated within the VHA received polypharmacy, and the utilization of clozapine
was several-fold lower. A large portion of patients started with polypharmacy as the initial
antipsychotic trial. In addition, there was unexplained variability between medical centers in use
of antipsychotic polypharmacy. Future research should consider the causes of variability and its
11

impact on patient outcomes. Pathways analysis is a useful way to use secondary data to inform
practical clinical trials and effectiveness of prescribing policies.
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Figure 1 Antipsychotic (AP) prescribing pathways among veterans with schizophrenia or schizoaffective disordera
AP1 to end of observation period
AP1

AP2 to end of observation period
AP1 + AP2

2 Monotherapy
3 Polypharmacy

AP1

AP1 + AP2

4 Polypharmacy

AP1

AP2 + AP3 or more

5 Polypharmacy

AP1

AP2

AP3 + AP4 or more

6 Polypharmacy

AP1

AP2

Clozapine

7 Clozapine

AP1

Clozapine

8 Early clozapine

AP1

AP2

AP3

9 Delay clozapine

AP1

AP2

No antipsychotic

10 Non-informative

AP1
a

1 Monotherapy

No antipsychotic treatment

11 Non-informative

Guideline-concordant pathways are in boldface.
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Figure 2 Rates of polypharmacy for treatment of schizophrenia or schizoaffective disorder, by
VHA facilitya

a

N indicates the facility denominator of total analytic sample cases. VHA, Veterans Health
Administration
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Table 1 Observed distribution of antipsychotic prescribing pathways for VHA patients with
schizophrenia or schizoaffective disordera
Pathway

Informative cases
Concordant with guidelines
Monotherapy without clozapine
Early use of clozapine
Clozapine
Subtotal
Nonconcordant with guidelines
Polypharmacy without clozapine
Polypharmacy with clozapine
Delayed use of clozapine
Subtotal
Total
Noninformative cases
Insufficient VHA antipsychotic trials
No VHA utilization
VHA utilization but no antipsychotics
dispensed
Total
Total
a
VHA, Veterans Health Administration

% total % informative
cases
cases
(N=1,923) (N=1,003)

N

745
17
1
763

39
1
<1
40

74
2
<1
76

188
7
45
240
1,003

10
<1
2
13
52

19
<1
5
24
100

272
310
338

14
16
18

920
1,923

48
100
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Table 2 Demographic and clinical characteristics of VHA patients with schizophrenia or
schizoaffective disordera

Characteristic

Nonclozapine
Total analytic sample monotherapy
(N=933)
(N=745)

Nonclozapine
polypharmacy
(N=188)

N

N

%

N

%

%

Caucasian
258
54
193
52
65
65
Hispanic
50
11
36
10
14
15
Male
863
93
699
94
164
87
Not married
417
45
332
45
85
46
Comorbidityb
Diabetes
152
16
123
17
29
15
Hyperlipidemia
156
17
115
15
41
22
a
VHA, Veterans Health Administration. Because of missing data, the denominator for percentages is not the group
maximum for all variables.
b
Patients may appear in more than one category.
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